Eyenovia, Inc. (NASDAQ:EYEN) Short Interest Update

Eyenovia, Inc. (NASDAQ:EYEN) was the recipient of a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 3,550,000 shares, an increase of 65.9% from the October 31st total of 2,140,000 shares. Based on an average trading volume of 4,600,000 shares, the days-to-cover ratio is currently 0.8 days.

Eyenovia Stock Performance

Shares of EYEN opened at $0.09 on Friday. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.58. The firm’s fifty day simple moving average is $0.42 and its two-hundred day simple moving average is $0.67. Eyenovia has a 12 month low of $0.08 and a 12 month high of $2.57. The stock has a market capitalization of $8.03 million, a P/E ratio of -0.13 and a beta of 1.75.

Eyenovia (NASDAQ:EYEN) last released its earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.02. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same quarter in the previous year, the company earned ($0.18) earnings per share. As a group, analysts predict that Eyenovia will post -0.5 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on EYEN. LADENBURG THALM/SH SH reaffirmed a “neutral” rating on shares of Eyenovia in a research note on Monday, November 18th. Brookline Capital Management reaffirmed a “hold” rating on shares of Eyenovia in a report on Friday, November 15th. HC Wainwright downgraded Eyenovia from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $12.00 to $2.00 in a research report on Monday, November 18th. Finally, William Blair reiterated a “market perform” rating on shares of Eyenovia in a report on Friday, November 15th.

Hedge Funds Weigh In On Eyenovia

Several institutional investors have recently made changes to their positions in the stock. Armistice Capital LLC acquired a new stake in Eyenovia in the 2nd quarter valued at $3,601,000. Vanguard Group Inc. lifted its stake in shares of Eyenovia by 25.2% in the first quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock valued at $1,765,000 after buying an additional 360,924 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Eyenovia by 36.6% during the third quarter. Geode Capital Management LLC now owns 557,994 shares of the company’s stock valued at $288,000 after buying an additional 149,471 shares during the last quarter. SkyView Investment Advisors LLC bought a new stake in shares of Eyenovia during the second quarter worth about $87,000. Finally, Financial Management Network Inc. acquired a new stake in shares of Eyenovia in the 3rd quarter worth about $39,000. Institutional investors and hedge funds own 25.84% of the company’s stock.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.